Senescent cell clearance by the immune system: Emerging therapeutic opportunities

•Senescent cells attract, anchor, and modulate the immune cells that can eliminate them.•We discuss different roles of immune cells in immune clearance of senescent cells.•Senescent cells accumulate with aging and disease in parallel with immune dysfunction.•We discuss relations between senescent ce...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in immunology 2018-12, Vol.40, p.101275-101275, Article 101275
Main Authors: Prata, Larissa G.P. Langhi, Ovsyannikova, Inna G., Tchkonia, Tamara, Kirkland, James L.
Format: Article
Language:English
Subjects:
Aging
Apoptosis
Cellular Senescence
Chemokines
Chronic Disease - therapy
Cytokines
Humans
Immune system
Immune System - physiology
Phenotype
Senescent cells
Senolytics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Senescent cells attract, anchor, and modulate the immune cells that can eliminate them.•We discuss different roles of immune cells in immune clearance of senescent cells.•Senescent cells accumulate with aging and disease in parallel with immune dysfunction.•We discuss relations between senescent cell accumulation and immune dysfunction.•Potential therapies could delay, prevent, or alleviate age-related disorders by targeting mechanisms linking senescent cells to immunological dysfunction. Senescent cells (SCs) arise from normal cells in multiple organs due to inflammatory, metabolic, DNA damage, or tissue damage signals. SCs are non-proliferating but metabolically active cells that can secrete a range of pro-inflammatory and proteolytic factors as part of the senescence-associated secretory phenotype (SASP). Senescent cell anti-apoptotic pathways (SCAPs) protect SCs from their own pro-apoptotic SASP. SCs can chemo-attract immune cells and are usually cleared by these immune cells. During aging and in multiple chronic diseases, SCs can accumulate in dysfunctional tissues. SCs can impede innate and adaptive immune responses. Whether immune system loss of capacity to clear SCs promotes immune system dysfunction, or conversely whether immune dysfunction permits SC accumulation, are important issues that are not yet fully resolved. SCs may be able to assume distinct states that interact differentially with immune cells, thereby promoting or inhibiting SC clearance, establishing a chronically pro-senescent and pro-inflammatory environment, leading to modulation of the SASP by the immune cells recruited and activated by the SASP. Therapies that enhance immune cell-mediated clearance of SCs could provide a lever for reducing SC burden. Such therapies could include vaccines, small molecule immunomodulators, or other approaches. Senolytics, drugs that selectively eliminate SCs by transiently disabling their SCAPs, may prove to alleviate immune dysfunction in older individuals and thereby accelerate immune-mediated clearance of SCs. The more that can be understood about the interplay between SCs and the immune system, the faster new interventions may be developed to delay, prevent, or treat age-related dysfunction and the multiple senescence-associated chronic diseases and disorders.
ISSN:1044-5323
1096-3618
DOI:10.1016/j.smim.2019.04.003